OSE Immunotherapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Marc Le Bozec
Chief executive officer
€400.0k
Total compensation
| CEO salary percentage | 25.00% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | €400k | €100k | -€38m |
Compensation vs Market: Marc's total compensation ($USD456.31K) is below average for companies of similar size in the US market ($USD655.15K).
Compensation vs Earnings: Insufficient data to compare Marc's compensation with company performance.
CEO
Marc Le Bozec (57 yo)
Mr. Marc Le Bozec is Director of OSE Immunotherapeutics SA from September 30, 2025 and served as its Interim Chief Executive Officer from October 02, 2025 until March 10, 2026 and is its Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | €400.00k | no data | |
| Deputy CEO & CFO | less than a year | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Medical Director | no data | no data | no data | |
| Chief Medical Officer Immuno-Oncology | 8.5yrs | no data | no data | |
| Chief Commercial Officer | 7.6yrs | no data | no data | |
| Chief Regulatory Officer | 4.6yrs | no data | no data | |
| Chief Clinical & Medical Research Officer | 4.6yrs | no data | no data | |
| Chief Business Officer | no data | no data | no data | |
| Chief Development Officer | 1.5yrs | no data | no data |
Experienced Management: ORPO.F's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | €400.00k | no data | |
| Independent Director | 2.5yrs | €28.57k | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Chairman of Board | less than a year | no data | no data | |
| Director of External Affairs & Member of the Scientific Advisory Board | 4.1yrs | €25.71k | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Director | less than a year | no data | 1.25% $ 1.1m | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Chairman of the Scientific Board | 12.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.1yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: ORPO.F's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 17:58 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OSE Immunotherapeutics SA is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Jyoti Prakash | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |